Prime Medicine ($PRME) Stock Forecast: Up 5.2% Today

What is Prime Medicine?

Prime Medicine (NASDAQ: PRME) is a company specializing in gene editing technologies. The stock is priced at approximately $3.43, with a market capitalization of $607.6 million. Analysts continue to uphold a "Moderate Buy" consensus rating, setting a target price of $7.38.

Why is Prime Medicine going up?

PRME stock is up 5.2% on Apr 13, 2026 16:35

• A recent downgrade to a "Strong Sell" rating appears to have initially caused a 6.4% decline in PRME's stock price.
• Despite the downgrade, the stock quickly recovered, indicating that some investors may have perceived the dip as a buying opportunity.
• Valuation metrics suggest that PRME is currently undervalued based on its forward PS ratio, potentially attracting value investors and contributing to the positive resurgence.
• Today's market movement for PRME reflects a combination of analyst assessments, valuation metrics, and investor actions, illustrating the ever-changing dynamics of stock prices in response to various influences.

PRME Price Chart

PRME Technical Analysis

PRME News

Prime Medicine (NASDAQ:PRME) Downgraded to "Strong Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded Prime Medicine (NASDAQ:PRME) from a "sell" to a "strong sell" rating. Despite this, other analysts offer a "Moderate Buy" consensus with a target price of $7.38, while the stock currently trades around $3.43. The company, focused on gene editing technologies, has seen significant institutional investor activity in the last quarter.

https://www.marketbeat.com/instant-alerts/prime-medicine-nasdaqprme-downgraded-to-strong-sell-rating-by-wall-street-zen-2026-04-11/

Prime Medicine (NASDAQ:PRME) Trading Down 6.4% - Here's What Happened

Prime Medicine (NASDAQ:PRME) saw its stock price drop by 6.4% on Friday, trading at $3.285 on significantly lower-than-average volume. Despite the decline, analysts hold a "Moderate Buy" consensus rating with an average price target of $7.38, including recent "strong-buy" and "outperform" initiations. The company has a market capitalization of $607.6 million, with a substantial portion of its stock owned by institutional investors.

https://www.marketbeat.com/instant-alerts/prime-medicine-nasdaqprme-trading-down-64-heres-what-happened-2026-04-10/

PRME PE Ratio & Valuation, Is PRME Overvalued

Prime Medicine Inc (PRME) is currently deemed "Undervalued" based on its forward PS ratio of 32.39 compared to its five-year average of -4.89, with a fair price estimated between $8.39 and $10.12 against its current price of $3.43. While its Price-to-Book ratio is higher than its 3 and 5-year averages, its P/S ratio of 31.57 is significantly below the competitor average of 288.07, raising concerns given its negative revenue growth. The analysis suggests that while PRME appears undervalued by some metrics, a deeper look into competitor valuations and revenue growth paints a more complex picture.

https://intellectia.ai/en/stock/PRME/valuation

Trending Today

Stanley Black & Decker Inc. ($SWK) Stock Forecast: Down 7.1% Today

Intuit Inc. ($INTU) Stock Forecast: Up 5.0% Today

MKS Instruments Inc. ($MKSI) Stock Forecast: Down 5.1% Today

Lam Research Corporation ($LRCX) Stock Forecast: Down 5.4% Today

Novavax Inc. ($NVAX) Stock Forecast: Up 5.4% Today

Verisk Analytics Inc. ($VRSK) Stock Forecast: Up 5.5% Today

KLA-Tencor Corporation ($KLAC) Stock Forecast: Down 5.1% Today

GoPro Inc. ($GPRO) Stock Forecast: Up 13.7% Today

Tesla Inc. ($TSLA) Stock Forecast: Up 7.0% Today

Eli Lilly and Company ($LLY) Stock Forecast: Down 5.0% Today

Prime Medicine Price History

02.03.2026 - PRME Stock was down 7.8%

• PRME stock experienced a significant 7.3% decline today, reaching an intraday low of $3.36 with reduced trading volume.
• The bearish movement could be attributed to market reactions following the news of the stock price drop, despite analysts maintaining a "Moderate Buy" consensus rating with a target price of $7.38.
• The upcoming pivotal year in 2026 for Prime Medicine's clinical ambitions, focusing on broader application of its gene-editing technology, might have raised concerns among investors about the company's ability to meet key milestones.
• The manufacturing breakthrough by Avaí Bio in regenerative medicine, addressing a critical hurdle in scaling production of living therapeutics, could have indirectly impacted PRME's stock performance as investors assess competitive dynamics in the sector.

24.01.2026 - PRME Stock was up 11.4%

• Jacob Funds' investment in Prime Medicine reflects growing confidence in the company's potential to revolutionize the treatment of various diseases through its precise gene editing capabilities.
• The positive results from Prime Medicine's first clinical trial are likely driving investor optimism and contributing to the bullish movement in PRME stock.
• The market's reaction suggests that investors see Prime Medicine as a promising player in the gene therapy space, with the potential for significant growth and impact in the healthcare industry.

03.02.2026 - PRME Stock was down 6.1%

• HighTower Advisors LLC and other institutional investors significantly increased their stakes in PRME, indicating confidence in the company's long-term prospects. However, this did not prevent the bearish movement in the market.
• The announcement of Prime Medicine's participation in investor conferences and the positive reception from investors initially boosted the stock price by 7.83%. However, this momentum was not sustained, leading to the bearish movement.
• The surge in call options trading and bullish sentiment among traders drove PRME shares up initially by 4.8%. Despite this positive activity, the overall market sentiment turned bearish.
• Participation in upcoming investor conferences to discuss Prime Medicine's innovative platform and therapeutic programs could potentially attract more investors in the future, but today's market movement seems to have been influenced by broader market trends rather than company-specific news.

06.02.2026 - PRME Stock was down 7.8%

• The bearish movement in PRME's stock today can be attributed to the company's ongoing financial struggles and widening losses, as highlighted by the recent quarterly report showing a significant net loss of $50.6 million.
• Despite an upgrade to a "strong-buy" rating by Lifesci Capital, the overall sentiment remains cautious among investors due to the company's consistent quarterly losses and projected revenue declines.
• The CEO's optimism about the FDA's new rare disease policies lowering costs may have provided some hope, but the market seems more focused on Prime Medicine's financial performance and the challenges it faces in sustaining operations.
• The company's focus on advancing its gene editing pipeline and engaging with the FDA for regulatory pathways could be potential catalysts for a turnaround in investor sentiment if successful in translating these efforts into positive clinical outcomes and revenue generation.

30.02.2026 - PRME Stock was down 5.2%

• PRME stock price dropped by 7.3% to $3.36, hitting an intraday low with lower trading volume, indicating increased selling pressure.
• Despite the decline, analysts maintain a "Moderate Buy" consensus rating with an average target price of $7.38, suggesting potential recovery in the future.
• Institutional investors like Alphabet, ARK, State Street, Vanguard, and Farallon have recently increased their stakes in the company, showing confidence in PRME's long-term prospects.
• The bearish movement could be attributed to profit-taking by some investors after a period of growth, coupled with general market volatility affecting biotech stocks.

05.02.2026 - PRME Stock was down 6.4%

• The CEO's positive remarks on FDA's new rare disease policies could potentially lead to lower costs for treatments, which might have raised concerns among investors about Prime Medicine's revenue prospects, contributing to the bearish market movement.
• Despite receiving a "strong-buy" rating from Lifesci Capital, Prime Medicine's reported losses in the last quarter and for the full year 2025, along with missing revenue estimates, have likely dampened investor sentiment and contributed to the bearish trend.
• The company's heavy spending phase, widening losses, and projected revenue declines as highlighted in the quarterly results may have reinforced the bearish narratives among investors, leading to a negative market movement for Prime Medicine.
• The affirmation of a cash runway into 2027 and the company's progress in advancing gene-editing therapies could be positive long-term indicators, but the immediate focus seems to be on the financial performance, causing the bearish sentiment in the market.

24.02.2026 - PRME Stock was down 5.7%

• PRME reported a Q4 loss and missed revenue estimates, leading to a negative sentiment among investors and analysts.
• The stock slipped following the Q4 updates, indicating potential concerns about the company's financial performance and future prospects.
• The disappointing financial results may have eroded investor confidence in PRME, causing the bearish movement in the stock price today.

26.01.2026 - PRME Stock was up 5.2%

• Unusual options trading activity with a significant increase in call options indicates a bullish sentiment among traders.
• The company's "Moderate Buy" consensus from analysts and substantial institutional investor stake add to the positive market momentum.
• Participation in upcoming investor conferences to discuss its Prime Editing platform and therapeutic programs likely boosted investor confidence, contributing to the stock's upward trend.

13.03.2026 - PRME Stock was up 5.2%

• A recent downgrade to a "Strong Sell" rating appears to have initially caused a 6.4% decline in PRME's stock price.
• Despite the downgrade, the stock quickly recovered, indicating that some investors may have perceived the dip as a buying opportunity.
• Valuation metrics suggest that PRME is currently undervalued based on its forward PS ratio, potentially attracting value investors and contributing to the positive resurgence.
• Today's market movement for PRME reflects a combination of analyst assessments, valuation metrics, and investor actions, illustrating the ever-changing dynamics of stock prices in response to various influences.

09.02.2026 - PRME Stock was up 7.0%

• The bullish movement in PRME stock today can be attributed to an initiation of coverage, highlighting the one-and-done potential of Prime Medicine's prime editing technology for liver and lung diseases. This positive outlook on the company's therapeutic prospects likely boosted investor confidence.
• Additionally, the CEO's comments on the FDA's new rare disease policies potentially lowering costs for treatments could have further contributed to the bullish sentiment surrounding PRME.
• Despite the quarterly loss reported by Prime Medicine, the upgraded "strong-buy" rating and the promising full-year financial results and business updates seem to have outweighed the bearish narratives, driving the stock's upward movement.

11.02.2026 - PRME Stock was down 9.0%

• Concerns may have arisen in the market regarding PRME's shift towards liver diseases, potentially impacting views on diversification and market prospects.
• Investors might be exercising caution despite positive mentions by LifeSci Capital, as PRME is well-funded until 2027, hinting at a longer timeline for generating revenue.
• The CEO's positive statements on potential FDA policy changes reducing costs for rare disease treatments may have been overlooked due to profit-taking or market uncertainties, contributing to the stock's bearish movement.

31.02.2026 - PRME Stock was up 5.7%

• PRME stock experienced a 7.3% decline, reaching an intraday low of $3.36 with reduced trading volume.
• Despite the drop, analysts maintain a "Moderate Buy" consensus rating with an average target price of $7.38.
• Institutional investors like Alphabet, ARK, State Street, Vanguard, and Farallon have increased their stakes in the company.
• The decline in stock price could be attributed to profit-taking after a previous bullish run, as investors reassess the company's progress in transitioning its gene-editing technology and upcoming regulatory filings.